MRD Bone Marrow Assessment in Pakistan at Chughtai Lab

Minimal Residual Disease (MRD) Assessment of Bone Marrow at Chughtai Lab

The Minimal Residual Disease (MRD) Assessment of Bone Marrow at Chughtai Lab is a highly sophisticated, state-of-the-art molecular and immunophenotypic evaluation designed to detect the presence of residual cancer cells in patients who have undergone treatment for hematologic malignancies. While conventional morphological assessment under a microscope can identify leukemia or lymphoma cells when they constitute more than 5% of the bone marrow, MRD testing can identify a single malignant cell among 10,000 to 1,000,000 healthy cells. This exceptional sensitivity makes MRD assessment the gold standard for evaluating treatment efficacy, predicting potential disease relapse, and guiding clinical decision-making in modern oncology.

At Chughtai Lab, this specialized diagnostic test utilizes advanced laboratory technologies, including multiparameter flow cytometry (MFC) and molecular assays such as quantitative Polymerase Chain Reaction (qPCR) and Next-Generation Sequencing (NGS). By analyzing bone marrow aspirate samples, hematopathologists can identify abnormal immunophenotypes or specific genetic mutations that characterize the patient’s original clone of leukemia, lymphoma, or multiple myeloma cells. The clinical utility of this test is profound; achieving an ‘MRD-negative’ status is a powerful indicator of deep clinical remission and is strongly associated with prolonged progression-free and overall survival. Conversely, the persistence of MRD, or its reappearance after a period of negativity, serves as an early warning sign of impending clinical relapse, allowing hematologists to initiate preemptive therapeutic interventions long before the disease manifests clinically or morphologically.

The bone marrow is the primary site of hematopoiesis, where red blood cells, white blood cells, and platelets are produced. In hematologic cancers, this microenvironment is disrupted by the uncontrolled proliferation of clonal malignant cells. By performing a targeted MRD assessment of the bone marrow, clinicians gain a direct, high-resolution view of the therapeutic response within this vital anatomical compartment. This test is indispensable for patients undergoing treatment for Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), and Multiple Myeloma (MM), providing the precise data needed to tailor personalized maintenance therapy, plan hematopoietic stem cell transplantation (HSCT), or adjust chemotherapy regimens.

Clinical Procedure: What to Expect

Patient Preparation

To ensure patient safety and the collection of a high-quality bone marrow specimen, specific preparation guidelines must be followed before the procedure:

• Informed Consent: The patient or their legal guardian must review and sign an informed consent form after the performing physician explains the benefits, risks, and steps of the bone marrow aspiration.
• Coagulation Profile: A recent Complete Blood Count (CBC) and coagulation profile, including Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), and International Normalized Ratio (INR), must be performed to assess bleeding risk.
• Medication Review: Patients must inform their physician of all medications they are taking. Anticoagulants (such as warfarin, heparin, or direct oral anticoagulants) and antiplatelet drugs (such as aspirin or clopidogrel) may need to be temporarily discontinued or adjusted under medical supervision.
• Allergy Notification: The patient must notify the healthcare team of any known allergies, especially to local anesthetics (like lidocaine), antiseptic solutions (like chlorhexidine or iodine), or latex.
• Fasting Requirements: If the procedure is performed under local anesthesia alone, fasting is generally not required. However, if conscious sedation or general anesthesia is planned, the patient must fast (no food or liquids) for 4 to 6 hours prior to the procedure.
• Hygiene and Attire: Patients should bathe or shower before the appointment and wear loose, comfortable clothing that allows easy access to the posterior hip area.

During the Procedure

The bone marrow aspiration is performed by a qualified hematologist, oncologist, or trained medical specialist in a controlled clinical environment. The step-by-step process includes:

• Patient Positioning: The patient is typically positioned in the prone (lying on the stomach) or lateral decubitus (lying on the side with knees bent) position to expose the posterior superior iliac spine (PSIS) of the pelvic bone.
• Sterile Preparation: The skin over the biopsy site is thoroughly cleaned with an antiseptic solution, and sterile drapes are placed around the area to maintain a sterile field.
• Local Anesthesia: A local anesthetic, typically 1% or 2% lidocaine, is infiltrated into the skin, subcutaneous tissues, and down to the periosteum (the highly sensitive outer layer of the bone) to minimize pain.
• Aspiration of Bone Marrow: Once the area is numb, a specialized bone marrow aspiration needle is inserted through the skin and cortex of the bone into the marrow cavity. A syringe is attached to the needle, and a small volume (typically 2 to 5 mL) of liquid bone marrow is aspirated. The patient may experience a brief, sharp, pulling or suction sensation during this step.
• Specimen Allocation: The collected bone marrow aspirate is immediately transferred into specific anticoagulant tubes (such as EDTA or sodium heparin) to prevent clotting and preserve cell viability for flow cytometry or molecular analysis.
• Post-Procedure Care: The needle is removed, and firm pressure is applied to the site for several minutes to control bleeding. A sterile pressure bandage is then applied. The patient is monitored for 30 to 60 minutes for any signs of bleeding, pain, or vasovagal reactions before being discharged.

When is a Minimal Residual Disease (MRD) Assessment of Bone Marrow Performed?

Acute Lymphoblastic Leukemia (ALL) Monitoring

In patients with Acute Lymphoblastic Leukemia (ALL), MRD assessment is performed at critical therapeutic milestones, such as at the end of induction therapy (typically day 28 or 33) and during consolidation phases. Because ALL has a high propensity for relapse, detecting subclinical levels of leukemic lymphoblasts is vital. Physicians request this test to determine if the patient has achieved a deep molecular response. If MRD is detected at these key time points, it indicates a higher risk of relapse, prompting clinicians to intensify chemotherapy, introduce targeted immunotherapies (such as blinatumomab), or prepare the patient for an allogeneic stem cell transplant.

Acute Myeloid Leukemia (AML) Surveillance

For patients with Acute Myeloid Leukemia (AML), MRD assessment is utilized to monitor the clearance of the leukemic clone after intensive chemotherapy or stem cell transplantation. AML is a highly heterogeneous disease, and MRD monitoring is tailored to specific molecular markers (such as NPM1 mutations, RUNX1-RUNX1T1, or CBFB-MYH11 fusions) or abnormal immunophenotypes identified at diagnosis. Physicians request this test to identify early molecular relapse, which often precedes morphological relapse by several weeks or months. This early detection provides a critical window of opportunity to initiate preemptive therapies, such as donor lymphocyte infusions or targeted inhibitors, to prevent full-blown clinical relapse.

Multiple Myeloma (MM) Response Assessment

In Multiple Myeloma (MM), MRD assessment is performed to evaluate the depth of response following autologous stem cell transplantation (ASCT) or during maintenance therapy. With the advent of highly effective novel agents, many myeloma patients achieve a complete response (CR) on conventional testing. However, residual clonal plasma cells often remain. Physicians utilize high-sensitivity MRD testing (at a sensitivity of 10^-5 or 10^-6) to confirm true MRD negativity. This information helps guide decisions regarding the duration and intensity of maintenance therapy, with MRD-negative patients experiencing significantly longer progression-free survival.

Chronic Lymphocytic Leukemia (CLL) Evaluation

MRD assessment in Chronic Lymphocytic Leukemia (CLL) is performed to evaluate the efficacy of modern, time-limited targeted therapies, such as combinations of BCL-2 inhibitors (venetoclax) and anti-CD20 monoclonal antibodies. Testing is typically conducted at the end of the planned treatment course. Physicians request MRD assessment of the bone marrow to confirm that the CLL clone has been eradicated below the clinical threshold. Achieving undetectable MRD (uMRD) in CLL is a major therapeutic goal, as it correlates with prolonged treatment-free intervals and allows for the safe discontinuation of therapy.

Pre- and Post-Hematopoietic Stem Cell Transplantation (HSCT)

In the context of hematopoietic stem cell transplantation, MRD assessment is performed both immediately prior to the transplant and at regular intervals post-transplant. Pre-transplant MRD status is one of the most powerful predictors of post-transplant outcomes; patients who are MRD-positive prior to conditioning therapy have a significantly higher risk of post-transplant relapse. Post-transplant MRD monitoring allows clinicians to track the kinetics of the donor chimerism and detect the re-emergence of recipient-derived malignant clones, enabling timely intervention with immunosuppression tapering or targeted therapies.

What Does a Minimal Residual Disease (MRD) Assessment of Bone Marrow Detect?

The Minimal Residual Disease (MRD) Assessment of Bone Marrow is designed to detect highly specific cellular, immunophenotypic, and molecular parameters, including:

• Aberrant Immunophenotypes: Cellular markers on malignant cells that differ from normal hematopoietic progenitors.
• Leukemia-Associated Immunophenotypes (LAIPs): Specific combinations of cell surface antigens identified at the time of diagnosis.
• Different-from-Normal (DfN) Patterns: Deviations in normal antigen expression pathways during cell maturation.
• Clonal Plasma Cells: Phenotypically abnormal plasma cells (typically CD138+, CD38+, CD19-, CD56+) in multiple myeloma.
• Clonal Immunoglobulin (Ig) Gene Rearrangements: Specific genetic rearrangements in B-cell lineages.
• Clonal T-Cell Receptor (TCR) Gene Rearrangements: Monoclonal rearrangements indicating T-cell malignancies.
• BCR-ABL1 Fusion Transcripts: The molecular signature of the Philadelphia chromosome in ALL or CML.
• PML-RARA Fusion Transcripts: The molecular driver of acute promyelocytic leukemia.
• RUNX1-RUNX1T1 (AML1-ETO) Transcripts: A key molecular marker in core-binding factor AML.
• CBFB-MYH11 Fusion Transcripts: Associated with inv(16) acute myeloid leukemia.
• NPM1 Mutation Burden: Quantifiable levels of mutated nucleophosmin 1 in AML.
• FLT3-ITD Allelic Ratio: Detection of internal tandem duplications in the FLT3 gene.
• KMT2A (MLL) Gene Rearrangements: Molecular abnormalities associated with high-risk leukemias.
• JAK2 V617F Mutation Burden: Quantifiable levels of the JAK2 mutation in myeloproliferative neoplasms.
• TP53 Mutations: High-risk genetic mutations associated with therapeutic resistance.
• Log-Reduction of Malignant Clone: The quantitative decrease in cancer cells compared to baseline levels.
• Asynchronous Antigen Expression: Simultaneous expression of early and late differentiation markers on a single cell.
• Lineage Infidelity: Expression of lymphoid markers on myeloid cells, or vice versa.
• Antigen Loss: The absence of normal lineage markers on clonal populations.
• Antigen Overexpression: Abnormally high density of specific receptors on the cell surface.
• Clonal Plasma Cell Light Chain Restriction: Monoclonal expression of either kappa or lambda light chains.
• Persistent Molecular Aberrations: The ongoing presence of diagnostic genetic markers despite morphological remission.
• Early Clonal Evolution: The emergence of new genetic or immunophenotypic subclones during treatment.
• Background Normal Myelopoiesis: The presence and proportion of healthy developing myeloid cells.
• Normal Erythroid Maturation: Assessment of healthy red blood cell precursors in the marrow.
• Normal Megakaryopoiesis: The presence of healthy platelet-producing megakaryocytes.
• Lymphoid Subpopulation Distribution: The balance of normal T-cells, B-cells, and NK-cells in the bone marrow.
• Hematopoietic Reconstitution Markers: Indicators of bone marrow recovery following intensive chemotherapy.

Turnaround Time and Report Access at Chughtai Lab

The Minimal Residual Disease (MRD) Assessment of Bone Marrow is a highly complex, specialized investigation requiring meticulous laboratory processing and expert interpretation by consultant hematopathologists. At Chughtai Lab, the turnaround time for MRD testing typically ranges from 5 to 10 working days, depending on the specific methodology required (such as multiparameter flow cytometry or advanced molecular assays like NGS and qPCR). Flow cytometry results are generally available within 3 to 5 working days, while complex molecular and genetic sequencing analyses may take up to 10 working days to ensure absolute accuracy.

Chughtai Lab provides seamless and convenient access to diagnostic reports. Once the report is finalized and signed off by the consultant hematopathologist, patients receive an automated SMS notification. Reports can be viewed, downloaded, and printed online through the official Chughtai Lab patient portal or the dedicated Chughtai Healthcare mobile application. Additionally, physical copies of the reports can be collected from any of Chughtai Lab’s numerous diagnostic centers and collection points located across Pakistan.

Minimal Residual Disease (MRD) Assessment of Bone Marrow Findings Overview

The following table outlines the key parameters evaluated during an MRD assessment, along with their normal and possible abnormal findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Leukemic Lymphoblasts (ALL)	Undetectable (MRD-negative, <0.01% or <10^-4 cells)	Detectable clonal lymphoblasts (MRD-positive, >=0.01% or >=10^-4 cells)
Myeloid Blast Immunophenotype (AML)	Normal hematopoietic maturation; no aberrant myeloid blasts detected	Presence of blasts with leukemia-associated immunophenotypes (LAIP) or different-from-normal (DfN) patterns
Clonal Plasma Cells (Multiple Myeloma)	No clonal plasma cells detected (sensitivity of 10^-5 to 10^-6)	Presence of phenotypically abnormal plasma cells (CD138+/CD38+/CD19-/CD56+) with light chain restriction
CLL Clonal B-Cells	Undetectable CLL cells (<1 CLL cell per 10,000 leukocytes)	Presence of clonal B-cells expressing CD5, CD19, CD20 (dim), and CD23
Molecular Fusion Transcripts (e.g., BCR-ABL1)	Undetectable fusion transcripts (complete molecular response)	Detectable fusion transcripts indicating molecular persistence or relapse
Gene Mutation Burden (e.g., NPM1)	Wild-type sequence; no mutated transcripts detected	Quantifiable levels of mutated NPM1 transcripts indicating residual disease
Immunoglobulin/TCR Gene Rearrangements	Polyclonal background; no dominant monoclonal rearrangements	Persistent monoclonal Ig or TCR gene rearrangements matching the diagnostic clone
Normal Hematopoiesis	Active, trilineage hematopoiesis with normal maturation profiles	Suppressed normal hematopoiesis, dysplastic changes, or delayed reconstitution

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Minimal Residual Disease (MRD) Assessment of Bone Marrow?

Choosing Chughtai Lab for this critical oncological investigation ensures the highest standards of diagnostic accuracy and clinical care:

• Experienced Healthcare Professionals: Our team includes highly qualified consultant hematopathologists, molecular biologists, and laboratory technologists specializing in complex hematologic malignancies.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the testing process, ensuring a supportive environment.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control standards and participates in rigorous external proficiency testing programs.
• Professional Reporting: Reports are detailed, clinically structured, and designed to provide clear, actionable data for treating oncologists and hematologists.
• Modern Diagnostic Approach: We utilize advanced diagnostic methodologies, including high-sensitivity multiparameter flow cytometry and precise molecular assays.
• Comfortable Environment: Our diagnostic centers and collection points are designed to provide a clean, professional, and comfortable experience for patients and their families.
• Convenient Location: With an extensive network of laboratories and collection centers across Pakistan, our services are easily accessible to patients nationwide.
• Commitment to Accurate Diagnosis: We understand the critical role of MRD testing in cancer management and are dedicated to delivering timely, precise, and reliable results to guide therapeutic decisions.